Bio Techne (Brazil) Today
| T1CH34 Stock | 11.69 0.07 0.60% |
PerformanceVery Weak
| Odds Of DistressLow
|
Bio Techne is trading at 11.69 as of the 19th of March 2025, a 0.60% increase since the beginning of the trading day. The stock's open price was 11.62. Bio Techne has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Moving together with Bio Stock
Moving against Bio Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Bio Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Bio Techne's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bio Techne or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Pres CEO | Charles Kummeth |
| Thematic Idea | IT (View all Themes) |
| Business Concentration | IT, Biotechnology, Healthcare, Computing (View all Sectors) |
Bio Techne (T1CH34) is traded on Sao Paulo Exchange in Brazil and employs 3,000 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 60.28 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bio Techne's market, we take the total number of its shares issued and multiply it by Bio Techne's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Bio Techne operates under Healthcare sector and is part of Biotechnology industry. The entity has 4.72 B outstanding shares.
Bio Techne generates positive cash flow from operations, but has no cash available
Check Bio Techne Probability Of Bankruptcy
Bio Techne Risk Profiles
Although Bio Techne's alpha and beta are two of the key measurements used to evaluate Bio Techne's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.03 | |||
| Standard Deviation | 3.5 | |||
| Variance | 12.22 | |||
| Risk Adjusted Performance | (0.02) |
Bio Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Bio Techne without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
Bio Techne Corporate Management
Elected by the shareholders, the Bio Techne's board of directors comprises two types of representatives: Bio Techne inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Techne's management team and ensure that shareholders' interests are well served. Bio Techne's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Techne's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Gavin | VP Devel | Profile | |
| Brenda JD | Gen VP | Profile | |
| Kim Kelderman | Pres Genomics | Profile | |
| David Clair | Sr Devel | Profile | |
| William Geist | Pres Segment | Profile |
Other Information on Investing in Bio Stock
Bio Techne financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio Techne security.